Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries

Bolin, Kristian; Wilson, Koo; Benhaddi, H.; Nigris, Enrico De; Marbaix, Sophie; Mörk, Ann‐Christin; Aubin, Henri‐Jean

doi:10.1093/eurpub/ckp075

Cited by 44 publications

(72 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A significant part of the intervention was smoking cessation programmes, either pharmacotherapy 4, 5, 36, 37, 38, 40, 41, 48, 50, 51, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, behavioural therapy 6, 42, 47, 66, 67, 68, 69 or a combination of these 33, 34, 35, 43, 45, 46, 49, 52, 54, 70, 71, 72, 73, 74, 75. Several studies evaluated wider tobacco control interventions 39, 44, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, whereas five studies included both smoking cessation programmes and tobacco control interventions 89, 90, 91, 92, 93.…”

Section: Resultsmentioning

confidence: 99%

“…In total, 23 of 64 studies reported QALY as their main outcome 5, 35, 38, 40, 41, 47, 48, 49, 56, 58, 59, 61, 62, 63, 65, 69, 70, 76, 78, 81, 86, 88, 94, followed by life years (LY) gained ( n = nine of 64) 33, 43, 46, 66, 67, 68, 73, 74, 89 or a combination of these ( n = 12 of 64) 4, 6, 35, 36, 37, 39, 42, 44, 57, 77, 80, 83. Five of 64 studies reported disability adjusted life years (DALY) as their main outcome 60, 82, 90, 91, 92, and only four of 64 (incremental) net benefit 52, 53, 55, 71.…”

Section: Resultsmentioning

confidence: 99%

“…Thirty of 64 studies used a Markov model, 12 of which used a specific type called the benefits of smoking cessation on outcomes (BENESCO) model 4, 5, 36, 37, 48, 56, 57, 58, 59, 61, 62, 65. Decision‐tree models 41, 43, 52, 55, 63, 71, 75, 83, 93, discrete‐event simulations (DES) 45, 54, the chronic disease model (RIVM‐CDM) 44, 81, 88, the tobacco policy model (TPM) 76, 77, the quit benefits model (QBM) 80, the World Health Organization (WHO) model 90, the global health outcomes model (GHO model) 70 and the abstinent‐contingent treatment model (ABT model) 73 were also used.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

et al. 2017

View full text Add to dashboard Cite

AimsTo identify different types of models used in economic evaluations of smoking cessation, analyse the quality of the included models examining their attributes and ascertain their transferability to a new context.MethodsA systematic review of the literature on the economic evaluation of smoking cessation interventions published between 1996 and April 2015, identified via Medline, EMBASE, National Health Service (NHS) Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA). The checklist‐based quality of the included studies and transferability scores was based on the European Network of Health Economic Evaluation Databases (EURONHEED) criteria. Studies that were not in smoking cessation, not original research, not a model‐based economic evaluation, that did not consider adult population and not from a high‐income country were excluded.FindingsAmong the 64 economic evaluations included in the review, the state‐transition Markov model was the most frequently used method (n = 30/64), with quality adjusted life years (QALY) being the most frequently used outcome measure in a life‐time horizon. A small number of the included studies (13 of 64) were eligible for EURONHEED transferability checklist. The overall transferability scores ranged from 0.50 to 0.97, with an average score of 0.75. The average score per section was 0.69 (range = 0.35–0.92). The relative transferability of the studies could not be established due to a limitation present in the EURONHEED method.ConclusionAll existing economic evaluations in smoking cessation lack in one or more key study attributes necessary to be fully transferable to a new context.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The BENESCO model has been used in numerous previous evaluations. [63][64][65][66][67][68][69][70][71][72][73] The model uses an annual cycle length and assumes that all smokers die at age 100 years, if death has not been simulated at an earlier age. A hypothetical cohort of 10,000 smokers enters the model, with each smoker assumed to make a single quit attempt, assisted by either varenicline or cytisine.…”

Section: The Conceptual Modelmentioning

confidence: 99%

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation

Leaviss

Sullivan

Ren

et al. 2014

Health Technology Assessment

View full text Add to dashboard Cite

“…This study compared smoking-related morbidity and mortality and the quality of the adjusted life-years gained and found varenicline to be more cost-effective than NRT. 36 Varenicline was also found to be more cost-effective and cost-saving compared to other smoking cessation treatments such as bupropion and nortriptyline. 4 Varenicline in the family practice setting…”

Section: Special Precaution In Patients With Mental Health Problemsmentioning

confidence: 99%

Varenicline: a new pharmacotherapy for smoking cessation in primary care practice

Robson¹

2011

South African Family Practice

View full text Add to dashboard Cite

Background: Cigarette smoking causes significant morbidity and mortality and is a major public health concern worldwide. Primary care doctors are in a unique position that enables them to promote smoking cessation, as smokers are more aware of their health at the time of their clinic visit. It is thus important to offer effective treatment to help smokers stop smoking.Methods: A search of PubMed was done up to 16 December 2009, using the keywords "varenicline" alone, "varenicline" and "family medicine", and "varenicline" and "primary care". The search produced 426 articles on varenicline. The articles that were chosen were case reports, meta-analyses, review articles and clinical trials published in English.Results: A new drug called varenicline has recently been introduced to assist smoking cessation. It is an α 4 β 2 nicotinic acetylcholine receptor partial agonist. Varenicline has a unique action that relieves the cravings and withdrawal symptoms that occur during smoking abstinence, while blocking the receptor and preventing any reward from additional smoking. It has been shown to be efficacious for smoking cessation in normal smokers; however, its safety in smokers with mental health problems needs to be elucidated. Conclusion:The currently available data support the effectiveness of varenicline to treat nicotine dependence, but caution is needed in smokers with mental health problems. Thus, primary care doctors have a new pharmacological option to offer smokers who wish to stop smoking.Peer reviewed.

show abstract

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries

Cited by 44 publications

References 23 publications

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation

Varenicline: a new pharmacotherapy for smoking cessation in primary care practice

Contact Info

Product

Resources

About